Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company engaged in the discovery and development of novel allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer. Leveraging advanced immunotherapy techniques, Adicet Bio is pioneering the use of gamma delta T cells engineered with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to create 'off-the-shelf' therapies aimed at providing durable and effective treatments for patients.
Core Products and Pipeline:
- ADI-001: A first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, currently in a Phase 1 clinical trial for relapsed or refractory aggressive B cell non-Hodgkin's lymphoma and autoimmune diseases such as lupus nephritis.
- ADI-270: An armored gamma delta CAR T cell product candidate targeting CD70, in preclinical development for renal cell carcinoma and other CD70+ solid and hematological malignancies.
Recent Achievements and Collaborations:
- FDA clearance of the Investigational New Drug (IND) application for ADI-001 in lupus nephritis and initiation of Phase 1 clinical trial expected in 2Q 2024.
- Strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics.
- Successful Series A financing round, raising $51 million led by Orbimed Partners, Orbimed Israel, and Novartis Ventures.
- Inducement awards granted to new employees as material inducements for employment, signifying ongoing growth and talent acquisition within the company.
- Presentation of promising preclinical data on ADI-270 at major scientific annual meetings, indicating robust anti-tumor activity and potential clinical benefits.
Financial Overview: Adicet Bio maintains a strong cash position with $247.6 million in cash and cash equivalents as of March 31, 2024, providing sufficient funding to support operations into the second half of 2026. The company continues to strategically invest in research and development, as well as in expanding its organizational capabilities.
Adicet Bio is at the forefront of innovation in the biotechnology space, striving to bring transformative therapies to patients with unmet medical needs. For more information, please visit Adicet Bio's official website.
Adicet Bio, Inc. (ACET) reported positive Phase 1 trial results for its investigational therapy, ADI-001, targeting relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). As of December 5, 2022, ADI-001 exhibited a 75% overall response rate (ORR) and a 69% complete response (CR) rate across all doses. Notably, in five patients previously treated with CAR T therapy, the ORR and CR were both 100%. The company aims to initiate pivotal studies in 2023, potentially leading to regulatory applications. No significant safety issues were reported, with treatment deemed well-tolerated.
Adicet Bio, Inc. (NASDAQ: ACET) will host a webcast on December 11, 2022, at 9:00 a.m. EST, to discuss the latest data from its Phase 1 study of ADI-001, targeting relapsed or refractory B-cell NHL. The presentation will feature Dr. Sattva Neelapu from MD Anderson Cancer Center, along with the Adicet management team. Participants can register on Adicet's website. An archived replay will be accessible for 30 days post-event. The company is focused on allogeneic gamma delta T cell therapies for cancer treatment.
Adicet Bio, Inc. (NASDAQ: ACET) announced on November 30, 2022, the grant of inducement awards to three new employees, totaling 38,400 stock options with an exercise price of $18.18 per share. Additionally, Dr. Nancy Boman, the company's newly appointed Senior VP and Chief Regulatory Officer, received an award for 136,000 stock options at the same exercise price. The options will vest over four years, contingent on continued employment. These grants were made outside the stockholder-approved equity plans, aligning with Nasdaq rules.
Adicet Bio, Inc. (NASDAQ: ACET) has announced that CEO Chen Schor will present at the virtual JMP Securities Hematology and Oncology Summit on December 6, 2022, at 9:40 a.m. ET. The presentation will focus on the company’s advancements in allogeneic gamma delta T cell therapies for cancer. Investors can access the live audio webcast on Adicet's website, with a replay available for 30 days post-event. Adicet is focused on engineered T cells aimed at enhancing anti-tumor responses, showcasing their innovative approach in oncology.
Adicet Bio, Inc. (NASDAQ: ACET) has appointed Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer. Dr. Boman will lead the regulatory strategy to enhance Adicet's gamma delta T cell therapy pipeline, including the initiation of a pivotal program for ADI-001 in the first half of 2023 and an IND application for ADI-925 in the second half of 2023. With nearly 30 years of experience in regulatory affairs, Dr. Boman previously held key roles at Encoded Therapeutics and AveXis, overseeing successful marketing applications.
Adicet Bio (ACET) reported promising safety and efficacy data for its lead candidate, ADI-001, targeting relapsed or refractory B-cell non-Hodgkin’s lymphoma. As of September 30, 2022, cash and cash equivalents were $282.7 million, providing a runway into the first half of 2025. R&D expenses rose to $16.6 million from $11.9 million year-over-year, while the net loss was $22.0 million, or $0.53 per share. The company plans to present updated data at the ASH Annual Meeting in December 2022 and outline new pipeline candidates at an R&D webcast on November 10, 2022.
Adicet Bio (ACET) announces promising preclinical data from four new gamma delta T cell therapy programs, showcased at the Society for Immunotherapy of Cancer's 37th Annual Meeting. The company plans to submit Investigational New Drug applications in the second half of 2023. CEO Chen Schor highlighted these developments as vital for advancing innovative cancer treatments. Adicet aims to enhance tumor targeting with its engineered therapies, which have shown increased efficacy in preclinical models. A detailed webcast is scheduled for November 10, 2022, to discuss these findings further.
Adicet Bio announced promising results from its Phase 1 study of ADI-001, targeting relapsed or refractory B-cell Non-Hodgkin's lymphoma. As of July 15, 2022, the therapy showed a 78% overall response rate and a 100% complete response rate in patients with prior CAR T therapy. No severe adverse events were reported, indicating a favorable safety profile. Adicet plans to present further data at the ASH Annual Meeting on December 10, 2022, and a webcast to discuss recent findings is scheduled for December 11, 2022.
Adicet Bio (NASDAQ: ACET) will have its CEO Chen Schor present at the Jefferies London Healthcare Conference from November 15-17, 2022. The presentation is scheduled for November 15 at 7:25 a.m. GMT. Interested parties can access the live audio webcast on Adicet Bio’s website, and an archived replay will be available for 30 days post-event.
Adicet is focused on developing allogeneic gamma delta T cell therapies for cancer, aiming to enhance anti-tumor immune response.
Adicet Bio, Inc. (NASDAQ: ACET) announced the granting of inducement awards on October 31, 2022, to 12 new hires under its 2022 Inducement Plan. The awards include non-qualified stock options to purchase 251,600 shares of common stock at an exercise price of $16.49 per share. Vesting will occur over four years, with one-fourth vesting after one year and the remainder in thirty-six equal monthly installments, contingent on continued employment. The inducement plan was approved by an independent board committee.
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
What is Adicet Bio, Inc.?
What are the key products in Adicet Bio's pipeline?
What recent achievements has Adicet Bio made?
How is Adicet Bio financially positioned?
What strategic collaborations has Adicet Bio entered into?
What is the focus of Adicet Bio's research and development?
What are ADI-001 and ADI-270?
What makes Adicet Bio's approach unique?
What is the significance of the FDA's fast track designation for ADI-001?
Where can I find more information about Adicet Bio?
